FAP and colorectal carcinoma: In keeping with these observations, a radiolabelled anti‐FAP antibody (sibrotuzumab) showed highly selective uptake by tumors but not normal tissues in patients with colorectal carcinoma or non‐small‐cell lung cancer.21